SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wahl RL, Zasadny KR, McFarlane D, Francis IR, Ross, CW, Estes J, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan phase I experience. J Nucl Med 1998;39: 21S27S.
  • 2
    Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 131623.
  • 3
    Kaminski MS, Gribbin T, Estes J, Ross, CW, Regan D, Zasadny K, et al. Iodine-131–anti B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions [Abstract 6]. American Society of Clinical Oncology Annual Meeting. Proc Am Soc Clin Oncol 1998;17:2a.
  • 4
    Wahl RL, Zasadny KR, McFarlane D, Estes J, Kison PV, Regan DD, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: single center experience with iodine-131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma. J Nucl Med 41:78P79P.
  • 5
    Zasadny KR, Rommelfanger SG, Regan DD, McCullough NT, Kroll S, Stagg R, et al. Tumor response predictors in radioimmunotherapy of previously untreated non-Hodgkin's lymphoma: (NHL) with iodine-131 tositumomab. J Nucl Med 2000; 41: 29P.
  • 6
    Koral KF, Dewaraja Y, Li J, Lin S, Barrett CL, Regan DD, et al. Initial results for hybrid SPECT-conjugate-view tumor dosimetry in I-131 anti-B1-antibody therapy of previously untreated lymphoma patients. J Nucl Med 2000; 41: 157986.
  • 7
    Koral KF, Dewaraja Y, Clarke LA, Li J, Zasadny KR, Rommelfanger SG, et al. Tumor absorbed dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report. Cancer Biother Radiopharm 2000; 15: 34755.
  • 8
    Finney DJ. Probit analysis. 3rd edition. Cambridge: Cambridge University Press, 1971.
  • 9
    Knox SJ, Goris ML, Davis TA, Trisler KD, Saal J, Levy R. Randomized controlled study of 131-I–anti-B1 versus unlabeled anti-B1 monoclonal antibody in patients with chemotherapy refractory low grade non-Hodgkin's lymphoma. J Radiat Oncol Biol Phys 1997; 39(Suppl): 326.